ArticleOncoTargets and therapy2021

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.

Haibo Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.